Pascale Christophe nackt sorted by

relevance

18-IL2 treated resectable recurrent stage 3 or 4 melanoma patients Richard Yang 1, Mark Albertini 2, Jacquelyn Hank 2, Hans Loibner 3, Stephen Gillies 4, Paul Sondel 2, Erik Ranheim 2 1 University of Wisconsin - Madison Hospitals and Clinics, Madison, WI, USA 2University of Wisconsin - Madison School of Medicine and Public Health, Madison, WI, USA 3Apeiron Biologics, Vienna, Austria 4Provenance Biopharmaceuticals, Carlisle, MA, USA Tumor infiltrating lymphocytes TILs Immune monitoring Clinical trial Biomarkers Tumor microenvironment Targeted therapy Surgery Immune contexture Clinical study Antibody P104 A study of PD-L1 diagnostic assay concordance in urothelial carcinoma Magdalena Zajac 1, Marietta Scott 1, Marianne Ratcliffe 2, Alan Sharpe 1, Paul W Scorer 1, Craig Barker 1, Hytham Al-Masri 3, Marlon Rebelatto 4, Jill Walker 1 1 AstraZeneca, Cambridge, United Kingdom 2AstraZeneca, Macclesfield, United Kingdom 3Hematogenix, Tinley Park, IL, USA 4Medimmune, Gaithersburg, MD, USA Biomarkers Targeted therapy P105 Infino: Bayesian inference to distinguish immune cell expression phenotypes, estimate immune infiltration into tumor microenvironment, and investigate exhausted T cell phenotype Maxim Zaslavsky 1, Jacqueline Buros Novik 1, Eliza Chang 1, Alexander Huang 2, Josephine Giles 2, Robert Orlowski 2, E.

But when you make movies like this "Immoral Women", you are bored with capital B.

69 Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, CA USA• 122 Melanoma Institute Australia, The University of Sydney, and Mater Hospital, Sydney, NSW Australia• Depending on the season, depending on weather, depending on time of day or night, the camera sweeps continuously the filmed location seaside, city or mountain and writes in real time the film of the artist's music.

14 Department of Pathology, University of Chicago, Chicago, IL USA• 165 CIC Biotherapie IGR Curie, CIC1428, Gustave Roussy Cancer Institute, Villejuif, France• 134 Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland• 46 Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden• 234 Dermatology and Oncology surgery of skin growths Department, Hospital of Caserta, Caserta, Italy• 151 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark• 74 Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN USA• 180 INSERM, U1138, Paris, France• Lehmann, Nikoletta Lendvai, Adam D.

129 Fox Chase Cancer Center, Philadelphia, PA USA• Callahan , Harriet Kluger , Michael A.

96 Division of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy• final materials distributed inside your organisation• 200 University Parthenope, Naples, Italy• 59 Gustave Roussy, Paris-Sud University, Villejuif Paris-Sud, France• Olszanski , Christine Gause , Lisa Chen , Jeffrey Chou , F.

41 INSERM team 15, Cordeliers Research Center, Paris, France• 31 Department of Immunology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213 USA• , Thousand Oaks, CA USA• 109 Department of Dermato Cancerology, Nantes University, Nantes, France• , Seattle, WA, USA 2Cytobank, Inc.

PMID: 25078557 Free PMC article.

.

88 Ludwig Center for Cancer Immunotherapy, Department of Immunology and Department of Medicine,, Memorial Sloan-Kettering Cancer Center, New York, NY USA• 213 Faculty of Medicine, Imperial College London, London, UK• , South San Francisco, CA USA• Petit 1, Lawrence Fong 2, Mark Stein 3, Ronald Tutrone 4, Anthony Mega 5, Naomi Haas 6 1 Advaxis Immunotherapies, Inc, Princeton, NJ, USA 2UCSF University of California, San Francisco, CA, USA 3The Cancer Institute of New Jersey CINJ Rutgers, Inc, New Brunswick, NJ, USA 4Chesapeake Urology Research Associates, Towson, MD, USA 5Lifespan Oncology Clinical Research, Providence, RI, USA 6University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA Tumor antigens Biomarkers Immune monitoring T cell Vaccine P3 Persistence of 6-thioguanine-resistant T-cell clones in a melanoma patient with durable antitumor response following treatment with immune checkpoint blockade.